古丽加娜提·努尔买买提;沙晶;玛依努尔·买买提;

• 1:新疆医科大学附属第八医院
• 2:新疆维吾尔自治区人民医院

摘要(Abstract)：

目的 检测视神经脊髓炎谱系疾病（NMOSD）急性期患者脑脊液中白细胞介素6(IL-6)及白细胞介素10(IL-10)水平，观察IL-6与IL-10在NMOSD急性期患者脑脊液中的表达。方法 选取AQP4抗体阳性的急性期NMOSD患者（NMOSD组）10例，13例年龄、性别匹配的健康者为对照组，应用ELISA方法测定10例急性期NMOSD患者及13健康对照者脑脊液中IL-6及IL-10的水平。结果 与对照组比较，NMOSD组脑脊液中IL-6水平升高，2组比较差异有统计学意义（P=0.01）;NMOSD组脑脊液IL-10水平降低，2组比较差异无统计学意义（P=0.33）。首发症状视神经炎的急性期NMOSD患者脑脊液IL-6水平较首发症状急性脊髓炎的急性期NMOSD患者高，差异有统计学意义（P=0.03）；急性脊髓炎和视神经炎患者脑脊液IL-10水平比较差异无统计学意义（P=0.58）。不同病程急性期NMOSD患者脑脊液IL-6、IL-10水平差异无统计学意义（P<0.05）。脑脊液IL-6水平与急性期NMOSD患者扩展残疾状态量表（EDSS）评分无显著相关性（P=0.49），脑脊液IL-10水平与急性期NMOSD患者EDSS评分有显著相关（P=0.01）。结论急性期NMOSD患者中IL-6水平升高并促进分泌自身抗体，发挥致病作用，IL-10也可能参与NMOSD发病过程。

关键词(KeyWords)： 视神经脊髓炎谱系疾病;白细胞介素6;白细胞介素10;水通道蛋白4抗体;脑脊液;急性期;扩展残疾状态量表

Abstract:

Keywords:

基金项目(Foundation): 新疆维吾尔自治区自然科学基金资助项目（编号：2019D01C150）

作者(Authors): 古丽加娜提·努尔买买提;沙晶;玛依努尔·买买提;

参考文献(References)：

• [1]WU Y,ZHONG L,GENG J.Neuromyelitis optica spectrum disorder:Pathogenesis,treatment,and experimental models[J].Mult Scler Relat Disord,2019,27:412-418.DOI:10.1016/j.msard.2018.12.002.
• [2]LENNON V A,WINGERCHUK D M,KRYZER T J,et al.Aserum autoantibody marker of neuromyelitis optica:distinction from multiple sclerosis[J].Lancet,2004,364(9451):2106-2112.DOI:10.1016/S0140-6736(04)17551-X.
• [3]KOWARIK M C,ASTLING D,GASPERI C,et al.CNSAquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder[J].Ann Clin Transl Neurol,2017,4(6):369-380.DOI:10.1002/acn3.418.
• [4]KAPLIN A I,DESHPANDE D M,SCOTT E,et al.IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis[J].J Clin Invest,2005,115(10):2731-2741.DOI:10.1172/JCI25141.
• [5]SATOH J,TABUNOKI H,YAMAMURA T,et al.Human astrocytes express aquaporin-1 and aquaporin-4 in vitro and in vivo[J].Neuropathology,2007,27(3):245-256.DOI:10.1111/j.1440-1789.2007.00774.x.
• [6]YANABA K,BOUAZIZ J D,HAAS K M,et al.A regulatory Bcell subset with a unique CD1dhi CD5+phenotype controls Tcell-dependent inflammatory responses[J].Immunity,2008,28(5):639-650.DOI:10.1016/j.immuni.2008.03.017.
• [7]HAN J,SUN L,FAN X,et al.Role of regulatory b cells in neuroimmunologic disorders[J].J Neurosci Res,2016,94(8):693-701.DOI:10.1002/jnr.23749.
• [8]QUAN C,YU H,QIAO J,et al.Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica:distinct from multiple sclerosis[J].Mult Scler,2013,19(3):289-298.DOI:10.1177/1352458512454771.
• [9]WINGERCHUK D M,BANWELL B,BENNETT J L,et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J].Neurology,2015,85(2):177-189.DOI:10.1212/WNL.0000000000001729.
• [10]KURTZKE J F.Rating neurologic impairment in multiple sclerosis:an expanded disability status scale(EDSS)[J].Neurology,1983,33(11):1444-1452.DOI:10.1212/wnl.33.11.1444.
• [11]MA X,KERMODE A G,HU X,et al.NMOSD acute attack:Understanding,treatment and innovative treatment prospect[J].J Neuroimmunol,2020,348:577387.DOI:10.1016/j.jneuroim.2020.577387.
• [12]仝延萍，杨涛，王静文，等.视神经脊髓炎谱系疾病缓解期患者外周血补体C5a及相关细胞因子水平与神经损伤的相关性[J].中国实用神经疾病杂志，2021,24(20):1749-1756.DOI:10.12083/SYSJ.2021.21.005.
• [13]刘勤，王建平，周晨光，等.AQP4阳性的视神经脊髓炎谱系疾病侧脑室白质损伤的影像学特点[J].中国实用神经疾病杂志，2021,24(20):1757-1765.DOI:10.12083/SYSJ.2021.20.009.
• [14]WANG Y,ZHOU Y,SUN X,et al.Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder[J].Neuroimmunomodulation,2016,23(5/6):352-358.DOI:10.1159/000464135.
• [15]TANAKA T,NARAZAKI M,KISHIMOTO T.IL-6 in inflammation,immunity,and disease[J].Cold Spring Harb Perspect Biol,2014,6(10):a016295.DOI:10.1101/cshperspect.a016295.
• [16]KOH S,KIM Y S,KIM M H,et al.Encephalitis with status epilepticus and stroke as complications of non-severe COVID-19 in a young female patient:a case report[J].BMCNeurol,2022,22(1):253.DOI:10.1186/s12883-022-02782-3.
• [17]EMMONS H A,WALLACE C W,FORDAHL S C.Interleukin-6and tumor necrosis factor-α attenuate dopamine release in mice fed a high-fat diet,but not medium or low-fat diets[J].Nutr Neurosci,2022:1-11.DOI:10.1080/1028415X.2022.2103613.
• [18]OOI S Z Y,SPENCER R J,HODGSON M,et al.Interleukin-6as a prognostic biomarker of clinical outcomes after traumatic brain injury:a systematic review[J].Neurosurg Rev,2022:1-20.DOI:10.1007/s10143-022-01827-y.
• [19]TAN Y,LIU H,OUYANG L,et al.Impact of Cerebrospinal Fluid Sample Handling on Cytokine Detection Results[J].Ann Clin Lab Sci,2022,52(3):470-474.
• [20]TRIANA-BALTZER G,TIMMERS M,DE BOER P,et al.Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture:A guide to sample type and time[J].Compr Psychoneuroendocrinol,2022,10:100116.DOI:10.1016/j.cpnec.2022.100116.
• [21]LIU D N,ZHOU J,HUANG X R,et al.Effect of electroacupuncture at“Shuigou”(GV26)and"Baihui"(GV20)on autophagy of hippo-campal neurons in rats with cerebral ischemia-reperfusion injury[J].Zhen Ci Yan Jiu,2022,47(6):491-496.DOI:10.13702/j.1000-0607.20210561.
• [22]PETR?ALKA M,MELUZíNOVáE,LIBERTíNOVáJ,et al.IL-2,IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis[J].PLo S One,2022,17(6):e0270607.DOI:10.1371/journal.pone.0270607.
• [23]FUJIHARA K,BENNETT J L,DE SEZE J,et al.Interleukin-6in neuromyelitis optica spectrum disorder pathophysiology[J].Neurol Neuroimmunol Neuroinflamm,2020,7(5):e841.DOI:10.1212/NXI.0000000000000841.
• [24]WANG H,WANG K,ZHONG X,et al.Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica[J].Neuroimmunomodulation,2012,19(5):304-308.DOI:10.1159/000339302.
• [25]WEI Y,CHANG H,LI X,et al.Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders:Significance of Interleukin-6[J].Neuroimmunomodulation,2018,25(4):215-224.DOI:10.1159/000494976.
• [26]ZHOU H S,CUI Z,WANG H,et al.The therapeutic effects of human embryonic stem cells-derived immunity-and-matrix regulatory cells on membranous nephropathy[J].Stem Cell Res Ther,2022,13(1):240.DOI:10.1186/s13287-022-02917-w.
• [27]SUN Y,LIU J,ZHOU Q,et al.Expression of LINC00638 in rheumatoid arthritis patients with damp-heat obstruction syndrome and the regulatory mechanisms for inflammation and oxidative stress[J].Zhong Nan Da Xue Xue Bao Yi Xue Ban,2022,47(2):183-193.DOI:10.11817/j.issn.1672-7347.2022.210376.
• [28]MICHéE-COSPOLITE M,BOUDIGOU M,GRASSEAU A,et al.Molecular Mechanisms Driving IL-10-Producing B Cells Functions:STAT3 and c-MAF as Underestimated Central Key Regulators?[J].Front Immunol,2022,13:818814.DOI:10.3389/fimmu.2022.818814.
• [29]GERTEL S,POLACHEK A,ELKAYAM O,et al.Lymphocyte activation gene-3(LAG-3) regulatory T cells:An evolving biomarker for treatment response in autoimmune diseases[J].Autoimmun Rev,2022,21(6):103085.DOI:10.1016/j.autrev.2022.103085.
• [30]MIYAGAKI T,FUJIMOTO M,SATO S.Regulatory B cells in human inflammatory and autoimmune diseases:from mouse models to clinical research[J].Int Immunol,2015,27(10):495-504.DOI:10.1093/intimm/dxv026.
• [31]YANG X,YANG J,CHU Y,et al.follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus[J].PLo S One,2014,9(2):e88441.DOI:10.1371/journal.pone.0088441.
• [32]PENTóN-ROL G,CERVANTES-LLANOS M,MARTíNEZ-SáNCHEZ G,et al.TNF-alpha and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica[J].J Inflamm(Lond),2009,6:18.DOI:10.1186/1476-9255-6-18.
• [33]CHO E B,CHO H J,SEOK J M,et al.The IL-10-producing regulatory B cells(B10 cells)and regulatory T cell subsets in neuromyelitis optica spectrum disorder[J].Neurol Sci,2018,39(3):543-549.DOI:10.1007/s10072-018-3248-y.
• [34]KHOROOSHI R,TOFTE-HANSEN E U,TYGESEN C,et al.Angiotensin AT2 receptor-induced interleukin-10 attenuates neuromyelitis optica spectrum disorder-like pathology[J].Mult Scler,2020,26(10):1187-1196.DOI:10.1177/1352458519860327.
• [35]WU Y,ZHONG L,GENG J.Neuromyelitis optica spectrum disorder:Pathogenesis,treatment,and experimental models[J].Mult Scler Relat Disord,2019,27:412-418.DOI:10.1016/j.msard.2018.12.002.30530071.
• [36]HUDA S,WHITTAM D,BHOJAK M,et al.Neuromyelitis optica spectrum disorders[J].Clin Med(Lond),2019,19(2):169-176.DOI:10.7861/clinmedicine.19-2-169.
• [37]WALLACH A I,TREMBLAY M,KISTER I.Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder[J].Neurol Clin,2021,39(1):35-49.DOI:10.1016/j.ncl.2020.09.003.
• [38]HOLROYD K B,MANZANO G S,LEVY M.Update on neuromyelitis optica spectrum Disorder[J].Curr Opin Ophthalmol,2020,31(6):462-468.DOI:10.1097/ICU.0000000000000703.
• [39]FUJIHARA K,BENNETT J L,DE SEZE J,et al.Interleukin-6in neuromyelitis optica spectrum disorder pathophysiology[J].Neurol Neuroimmunol Neuroinflamm,2020,7(5):e841.doi:10.1212/NXI.0000000000000841.
• [40]HOLM?Y T,H?GLUND R A,ILLES Z,et al.Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder[J].J Neurol,2021,268(12):4522-4536.DOI:10.1007/s00415-020-10235-5.
• [41]WINGERCHUK D M,LUCCHINETTI C F.Neuromyelitis Optica Spectrum Disorder[J].N Engl J Med,2022,387(7):631-639.DOI:10.1056/NEJMra1904655.
• [42]RAMAKRISHNAN P,NAGARAJAN D.Neuromyelitis optica spectrum disorder:an Overview[J].Acta Neurobiol Exp(Wars),2020,80(3):256-272.
• [43]WALISZEWSKA-PROSó?M,CHOJDAK-?UKASIEWICZ J,BUDREWICZ S,et al.Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects[J].Int J Mol Sci,2021,22(6):2801.DOI:10.3390/ijms22062801.
• [44]PITTOCK S J,ZEKERIDOU A,WEINSHENKER B G.Hope for patients with neuromyelitis optica spectrum disorders-from mechanisms to trials[J].Nat Rev Neurol,2021,17(12):759-773.DOI:10.1038/s41582-021-00568-8.
• [45]CLARKE L,ARNETT S,LILLEY K,et al.Magnetic resonance imaging in neuromyelitis optica spectrum disorder[J].Clin Exp Immunol,2021,206(3):251-265.DOI:10.1111/cei.13630.
• [46]SHAHMOHAMMADI S,DOOSTI R,SHAHMOHAMMADI A,et al.Neuromyelitis optica spectrum disorder(NMOSD)associated with cancer:A systematic review[J].Mult Scler Relat Disord,2021,56:103227.DOI:10.1016/j.msard.2021.103227.
• [47]ZHANG X,XU Y,PEI LJ.Review of Neuromyelitis Optica Spectrum Disorder with Pain-Depression Comorbidity[J].Chin Med Sci J,2021,36(4):316-322.DOI:10.24920/003859.